Challenges of modifying disease progression in prediagnostic Parkinson's disease
Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its m...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Salat, David [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016transfer abstract |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport - Fang, Jun ELSEVIER, 2014transfer abstract, London |
|---|---|
| Übergeordnetes Werk: |
volume:15 ; year:2016 ; number:6 ; pages:637-648 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1474-4422(16)00060-0 |
|---|
| Katalog-ID: |
ELV029523273 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV029523273 | ||
| 003 | DE-627 | ||
| 005 | 20230625174308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1474-4422(16)00060-0 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016004000010.pica |
| 035 | |a (DE-627)ELV029523273 | ||
| 035 | |a (ELSEVIER)S1474-4422(16)00060-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.17 |2 bkl | ||
| 084 | |a 58.50 |2 bkl | ||
| 084 | |a 43.12 |2 bkl | ||
| 100 | 1 | |a Salat, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Challenges of modifying disease progression in prediagnostic Parkinson's disease |
| 264 | 1 | |c 2016transfer abstract | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. | ||
| 520 | |a Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. | ||
| 700 | 1 | |a Noyce, Alastair J |4 oth | |
| 700 | 1 | |a Schrag, Anette |4 oth | |
| 700 | 1 | |a Tolosa, Eduardo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Lancet Publ. Group |a Fang, Jun ELSEVIER |t Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |d 2014transfer abstract |g London |w (DE-627)ELV017537959 |
| 773 | 1 | 8 | |g volume:15 |g year:2016 |g number:6 |g pages:637-648 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1474-4422(16)00060-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_70 | ||
| 936 | b | k | |a 35.17 |j Katalyse |q VZ |
| 936 | b | k | |a 58.50 |j Umwelttechnik: Allgemeines |q VZ |
| 936 | b | k | |a 43.12 |j Umweltchemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 15 |j 2016 |e 6 |h 637-648 |g 12 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
d s ds |
|---|---|
| matchkey_str |
salatdavidnoycealastairjschraganettetolo:2016----:hlegsfoiyndsaergesoipeigo |
| hierarchy_sort_str |
2016transfer abstract |
| bklnumber |
35.17 58.50 43.12 |
| publishDate |
2016 |
| allfields |
10.1016/S1474-4422(16)00060-0 doi GBVA2016004000010.pica (DE-627)ELV029523273 (ELSEVIER)S1474-4422(16)00060-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Salat, David verfasserin aut Challenges of modifying disease progression in prediagnostic Parkinson's disease 2016transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Noyce, Alastair J oth Schrag, Anette oth Tolosa, Eduardo oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:15 year:2016 number:6 pages:637-648 extent:12 https://doi.org/10.1016/S1474-4422(16)00060-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 15 2016 6 637-648 12 045F 610 |
| spelling |
10.1016/S1474-4422(16)00060-0 doi GBVA2016004000010.pica (DE-627)ELV029523273 (ELSEVIER)S1474-4422(16)00060-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Salat, David verfasserin aut Challenges of modifying disease progression in prediagnostic Parkinson's disease 2016transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Noyce, Alastair J oth Schrag, Anette oth Tolosa, Eduardo oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:15 year:2016 number:6 pages:637-648 extent:12 https://doi.org/10.1016/S1474-4422(16)00060-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 15 2016 6 637-648 12 045F 610 |
| allfields_unstemmed |
10.1016/S1474-4422(16)00060-0 doi GBVA2016004000010.pica (DE-627)ELV029523273 (ELSEVIER)S1474-4422(16)00060-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Salat, David verfasserin aut Challenges of modifying disease progression in prediagnostic Parkinson's disease 2016transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Noyce, Alastair J oth Schrag, Anette oth Tolosa, Eduardo oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:15 year:2016 number:6 pages:637-648 extent:12 https://doi.org/10.1016/S1474-4422(16)00060-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 15 2016 6 637-648 12 045F 610 |
| allfieldsGer |
10.1016/S1474-4422(16)00060-0 doi GBVA2016004000010.pica (DE-627)ELV029523273 (ELSEVIER)S1474-4422(16)00060-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Salat, David verfasserin aut Challenges of modifying disease progression in prediagnostic Parkinson's disease 2016transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Noyce, Alastair J oth Schrag, Anette oth Tolosa, Eduardo oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:15 year:2016 number:6 pages:637-648 extent:12 https://doi.org/10.1016/S1474-4422(16)00060-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 15 2016 6 637-648 12 045F 610 |
| allfieldsSound |
10.1016/S1474-4422(16)00060-0 doi GBVA2016004000010.pica (DE-627)ELV029523273 (ELSEVIER)S1474-4422(16)00060-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Salat, David verfasserin aut Challenges of modifying disease progression in prediagnostic Parkinson's disease 2016transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. Noyce, Alastair J oth Schrag, Anette oth Tolosa, Eduardo oth Enthalten in Lancet Publ. Group Fang, Jun ELSEVIER Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport 2014transfer abstract London (DE-627)ELV017537959 volume:15 year:2016 number:6 pages:637-648 extent:12 https://doi.org/10.1016/S1474-4422(16)00060-0 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 35.17 Katalyse VZ 58.50 Umwelttechnik: Allgemeines VZ 43.12 Umweltchemie VZ AR 15 2016 6 637-648 12 045F 610 |
| language |
English |
| source |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:15 year:2016 number:6 pages:637-648 extent:12 |
| sourceStr |
Enthalten in Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport London volume:15 year:2016 number:6 pages:637-648 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Katalyse Umwelttechnik: Allgemeines Umweltchemie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| authorswithroles_txt_mv |
Salat, David @@aut@@ Noyce, Alastair J @@oth@@ Schrag, Anette @@oth@@ Tolosa, Eduardo @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV017537959 |
| dewey-sort |
3610 |
| id |
ELV029523273 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029523273</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625174308.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(16)00060-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016004000010.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029523273</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(16)00060-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Salat, David</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Challenges of modifying disease progression in prediagnostic Parkinson's disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Noyce, Alastair J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schrag, Anette</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tolosa, Eduardo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:637-648</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(16)00060-0</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2016</subfield><subfield code="e">6</subfield><subfield code="h">637-648</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Salat, David |
| spellingShingle |
Salat, David ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 Challenges of modifying disease progression in prediagnostic Parkinson's disease |
| authorStr |
Salat, David |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV017537959 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl Challenges of modifying disease progression in prediagnostic Parkinson's disease |
| topic |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_unstemmed |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| topic_browse |
ddc 610 ddc 570 ddc 540 bkl 35.17 bkl 58.50 bkl 43.12 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a j n aj ajn a s as e t et |
| hierarchy_parent_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| hierarchy_parent_id |
ELV017537959 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV017537959 |
| title |
Challenges of modifying disease progression in prediagnostic Parkinson's disease |
| ctrlnum |
(DE-627)ELV029523273 (ELSEVIER)S1474-4422(16)00060-0 |
| title_full |
Challenges of modifying disease progression in prediagnostic Parkinson's disease |
| author_sort |
Salat, David |
| journal |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| journalStr |
Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
637 |
| author_browse |
Salat, David |
| container_volume |
15 |
| physical |
12 |
| class |
610 610 DE-600 570 VZ 540 VZ 35.17 bkl 58.50 bkl 43.12 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Salat, David |
| doi_str_mv |
10.1016/S1474-4422(16)00060-0 |
| dewey-full |
610 570 540 |
| title_sort |
challenges of modifying disease progression in prediagnostic parkinson's disease |
| title_auth |
Challenges of modifying disease progression in prediagnostic Parkinson's disease |
| abstract |
Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. |
| abstractGer |
Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. |
| abstract_unstemmed |
Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_70 |
| container_issue |
6 |
| title_short |
Challenges of modifying disease progression in prediagnostic Parkinson's disease |
| url |
https://doi.org/10.1016/S1474-4422(16)00060-0 |
| remote_bool |
true |
| author2 |
Noyce, Alastair J Schrag, Anette Tolosa, Eduardo |
| author2Str |
Noyce, Alastair J Schrag, Anette Tolosa, Eduardo |
| ppnlink |
ELV017537959 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/S1474-4422(16)00060-0 |
| up_date |
2024-07-06T21:41:12.634Z |
| _version_ |
1803867466116366336 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029523273</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625174308.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1474-4422(16)00060-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016004000010.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029523273</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1474-4422(16)00060-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.17</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.50</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Salat, David</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Challenges of modifying disease progression in prediagnostic Parkinson's disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials. Advances in the understanding of this prediagnostic phase of Parkinson's disease (for which the clinical diagnostic and prognostic markers used in more advanced disease stages are not applicable) will lead to the identification of biomarkers of neurodegeneration and its progression. These biomarkers will, in turn, help to identify the optimum population to be included and the most appropriate outcomes to be assessed in trials of disease-modifying drugs. Potential risks to minimally symptomatic participants, some of whom might not progress to manifest Parkinson's disease, and individuals who do not wish to know their mutation carrier status, could pose specific ethical dilemmas in the design of these trials.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Noyce, Alastair J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schrag, Anette</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tolosa, Eduardo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Lancet Publ. Group</subfield><subfield code="a">Fang, Jun ELSEVIER</subfield><subfield code="t">Rejection and modeling of arsenate by nanofiltration: Contributions of convection, diffusion and electromigration to arsenic transport</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV017537959</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:6</subfield><subfield code="g">pages:637-648</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1474-4422(16)00060-0</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.17</subfield><subfield code="j">Katalyse</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.50</subfield><subfield code="j">Umwelttechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2016</subfield><subfield code="e">6</subfield><subfield code="h">637-648</subfield><subfield code="g">12</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.402112 |